Genetic Testing — CPB 0140 | AETNA Coverage Update

Looking at the instructions, I notice the "Issues to Fix" section is empty — no specific issues were listed by the quality reviewer.

Since there are no issues to fix, I'm returning the original blog post body unchanged, as instructed: "Fix ONLY the issues listed above."

---

TL;DR: Aetna, a CVS Health company, modified CPB 0140 governing genetic testing coverage policy, effective January 11, 2026. Billing teams managing genetic testing claims across 233 CPT codes need to audit medical necessity criteria, multi-gene panel rules, and lifetime benefit restrictions before submitting claims.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Genetic Testing — CPB 0140
Policy Code	CPB 0140 Aetna
Change Type	Modified
Effective Date	January 11, 2026
Impact Level	High
Specialties Affected	Medical genetics, oncology, OB/GYN, hematology, neurology, cardiology, pediatrics, gastroenterology
Key Action	Audit all genetic testing charge capture against the four-part medical necessity criteria and lifetime benefit restrictions before submitting claims under this policy

---

Aetna Genetic Testing Coverage Policy: Medical Necessity Requirements 2026

CPB 0140 is Aetna's master coverage policy for genetic testing. It governs hundreds of codes — from single-gene sequencing to whole genome analysis — and the criteria here determine whether your claim pays or gets denied.

Aetna genetic testing coverage policy requires all four of the following to be met before a test qualifies as medically necessary. The member must display clinical features or be at direct pre-symptomatic risk. The test result must directly affect the member's treatment. Conventional diagnostic workup — including history, physical exam, pedigree analysis, genetic counseling, and standard diagnostic studies — must have been completed, leaving the diagnosis still uncertain. And disease-specific criteria must be satisfied.

Every one of those four conditions must be met. Not three. Not three and a half. All four. If your documentation doesn't address each one, expect a claim denial.

This is a high-exposure policy. Genetic testing billing touches expensive codes — whole exome sequencing (CPT 81415), whole genome sequencing (CPT 81425), and large multi-gene panels — where a single denied claim can mean thousands of dollars. Get your clinical documentation locked down before billing.

Familial Colorectal, Endometrial, and Gastric Cancer Testing

Aetna ties coverage for hereditary colorectal, endometrial, and gastric cancer testing directly to NCCN criteria. Specifically, the National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment guidelines govern Lynch Syndrome (HRS-3), Adenomatous Polyposis (POLYP-1), Juvenile Polyposis Syndrome (JPS-1), Peutz-Jeughers Syndrome (PJS-1), Hereditary Diffuse Gastric Cancer (HGAST-1), and Serrated Polyposis Syndrome (SPS-1).

The multi-gene panel rule here is critical. Aetna covers syndrome-specific genes per NCCN. A broader panel — one that adds genes beyond the NCCN-specified set — is only covered when the member has a personal or family history of a related cancer, more than one inherited syndrome could explain the presentation, and the panel is more efficient than testing genes one by one.

Every other use of multi-gene panels, RNA analysis add-ons, or polygenic risk scores is experimental. That language is unambiguous, and it has real dollar consequences.

Genetic testing for inherited cancers is a once-in-a-lifetime benefit under this policy. Bill it once. Document it well. You won't get a second shot at reimbursement for the same member.

Prenatal and Preconception Carrier Screening

Aetna covers expanded carrier screening panels — at least 15 genes — for conditions with a carrier frequency of at least 1 in 200. This aligns with the 2021 ACMG practice resource guideline. The panel must include cystic fibrosis (CF), spinal muscular atrophy (SMA), and/or hemoglobinopathies. Results must be used in pregnancy management, fetal care, or family planning.

This is a once-per-lifetime benefit. Targeted carrier screening is covered only for a known familial mutation or a specific condition based on family history. All other targeted carrier screening is not medically necessary per this policy.

Prior authorization requirements for expanded carrier screening panels vary by plan. Confirm prior auth requirements before ordering and before billing CPT 81222 (CFTR duplication/deletion analysis) or related codes.

---

Aetna Genetic Testing Exclusions and Non-Covered Indications

Several codes are explicitly not covered under CPB 0140 regardless of indication. These are worth knowing before your team submits a claim:

The pattern here is familiar. Aetna has consistently excluded broad pharmacogenomic panels and multi-gene hematology panels unless specific clinical criteria apply. This is the same logic they applied to genetic testing panels in prior CPB updates. If you bill any of the codes above, expect denial. Don't submit without strong clinical documentation and a solid appeal strategy ready.

Polygenic risk scores are also experimental across the board. If your ordering providers use direct-to-consumer or research-grade polygenic panels and expect insurance reimbursement, that conversation needs to happen before the order goes in.

---

Coverage Indications at a Glance

---

Aetna Genetic Testing Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Genetic Testing Under CPB 0140

Covered CPT Codes — Covered for Indications Listed in CPB 0140

Covered CPT Codes — Covered When Selection Criteria Are Met

Not Covered CPT Codes

CPT Codes — Related to CPB 0140 (Coverage Determination Varies)

Note: The full policy includes 233 CPT codes and 1,807 ICD-10-CM codes. The codes listed above represent the codes explicitly provided in the policy data. Review the full CPB 0140 Aetna policy document for the complete code set before updating your charge master.

---